

Giovanni Scambia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8501625/publications.pdf>

Version: 2024-02-01

68
papers

9,213
citations

201674

27
h-index

118850

62
g-index

68
all docs

68
docs citations

68
times ranked

7914
citing authors

#	ARTICLE	IF	CITATIONS
1	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2495-2505.	27.0	1,854
2	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1274-1284.	10.7	1,376
3	Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1707-1716.	6.3	1,316
4	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 1949-1961.	13.7	1,261
5	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2416-2428.	27.0	1,176
6	Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. <i>European Journal of Cancer</i> , 2016, 59, 22-33.	2.8	297
7	Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1657-1664.	2.5	220
8	Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICOâ€”The MIMOSA Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 1554-1561.	1.6	126
9	Optimizing treatment in recurrent epithelial ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1147-1158.	2.4	107
10	A multicentric trial (Olympiaâ€”MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 209, 462.e1-462.e11.	1.3	106
11	Hysteroscopic Treatment of Symptomatic Cesarean-induced Isthmocele: A Prospective Study. <i>Journal of Minimally Invasive Gynecology</i> , 2015, 22, 297-301.	0.6	104
12	Comparison of Different Surgical Approaches for Stage IB1 Cervical Cancer Patients: A Multi-institution Study and a Review of the Literature. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1020-1028.	2.5	80
13	Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. <i>Gynecologic Oncology</i> , 2019, 154, 441-448.	1.4	74
14	Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 465-478.	10.7	70
15	Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trialâ€”NCT02324595): a feasibility study. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 503.e1-503.e6.	1.3	66
16	BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 334.e1-334.e9.	1.3	65
17	Survival After Curative Pelvic Exenteration for Primary or Recurrent Cervical Cancer: A Retrospective Multicentric Study of 167 Patients. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 916-922.	2.5	61
18	Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 632.e1-632.e8.	1.3	60

#	ARTICLE	IF	CITATIONS
19	A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. <i>Oncologist</i> , 2020, 25, e311-e320.	3.7	56
20	Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort study. <i>BMJ, The</i> , 2020, 370, m2614.	6.0	54
21	ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 961-982.	2.5	54
22	Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2014, 28, 1808-1815.	2.4	44
23	Î ² -arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer. <i>Nature Communications</i> , 2019, 10, 3196.	12.8	40
24	Substantial lymph-vascular space invasion (LVSI) as predictor of distant relapse and poor prognosis in low-risk early-stage endometrial cancer. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e11.	2.2	38
25	Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases. <i>European Journal of Surgical Oncology</i> , 2019, 45, 2096-2102.	1.0	37
26	Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1450-1454.	2.5	33
27	Minimally Invasive Approach in Type II Endometrial Cancer: Is It Wise and Safe?. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 438-445.	0.6	32
28	Ovarian Cancer Management in the Oldest Old: Improving Outcomes and Tailoring Treatments. , 2017, 8, 677.		31
29	Neo-adjuvant platinum-based chemotherapy followed by chemoradiation and radical surgery in locally advanced cervical cancer (Lacc) patients: A phase II study. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1062-1068.	1.0	28
30	Tumor Size, an Additional Risk Factor of Local Recurrence in Low-Risk Endometrial Cancer: A Large Multicentric Retrospective Study. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 684-691.	2.5	24
31	Semiquantitative evaluation of lymph-vascular space invasion in patients affected by endometrial cancer: Prognostic and clinical implications. <i>European Journal of Cancer</i> , 2021, 142, 29-37.	2.8	24
32	Role of blue dye for sentinel lymph node detection in early endometrial cancer. <i>Gynecological Surgery</i> , 2017, 14, 23.	0.9	21
33	Ultrasoundâ€guided FNA cytology of groin lymph nodes improves the management of squamous cell carcinoma of the vulva: Results from a comparative cytohistological study. <i>Cancer Cytopathology</i> , 2019, 127, 514-520.	2.4	19
34	Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach. <i>Gynecologic Oncology</i> , 2020, 158, 740-746.	1.4	17
35	Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 445-453.	2.4	15
36	Dose-dense paclitaxel/carboplatin as neo-adjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer: a prospective phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 431-438.	2.3	14

#	ARTICLE	IF	CITATIONS
37	External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 67-73.	2.5	14
38	Personalized Clinical Phenotyping through Systems Medicine and Artificial Intelligence. <i>Journal of Personalized Medicine</i> , 2021, 11, 265.	2.5	14
39	Anatomical distribution of sentinel lymph nodes in patients with endometrial cancer: a multicenter study. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 517-524.	2.5	13
40	Fusion imaging of ultrasound and MRI in the assessment of locally advanced cervical cancer: a prospective study. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 456-465.	2.5	12
41	Intra-operative assessment of sentinel lymph node status by one-step nucleic acid amplification assay (OSNA) in early endometrial cancer: a prospective study. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1016-1020.	2.5	11
42	Is a Vaginectomy Enough or is a Pelvic Exenteration Always Required for Surgical Treatment of Recurrent Cervical Cancer? A Propensity-Matched Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 3281-3290.	1.5	11
43	Sentinel Lymph Node in Aged Endometrial Cancer Patients – The SAGE Study – A Multicenter Experience. <i>Frontiers in Oncology</i> , 2021, 11, 737096.	2.8	11
44	Tolerability of Bevacizumab in elderly Ovarian cancer patients (TURBO study): a case-control study of a real-life experience. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e6.	2.2	10
45	Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence. <i>OncoTargets and Therapy</i> , 2014, 7, 1273.	2.0	9
46	The personalized medicine discourse: archaeology and genealogy. <i>Medicine, Health Care and Philosophy</i> , 2021, 24, 247-253.	1.8	9
47	Ultrasound evaluation of ovarian masses and assessment of the extension of ovarian malignancy. <i>British Journal of Radiology</i> , 2021, 94, 20201375.	2.2	9
48	Risk Factors for Anastomotic Leakage in Advanced Ovarian Cancer Surgery: A Large Single-Center Experience. <i>Annals of Surgical Oncology</i> , 2022, 29, 4791-4802.	1.5	9
49	Survival in clinical stage I endometrial cancer with single vs. multiple positive pelvic nodes: results of a multi-institutional Italian study. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e100.	2.2	8
50	Incidence, predictors and clinical outcome of pancreatic fistula in patients receiving splenectomy for advanced or recurrent ovarian cancer: a large multicentric experience. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 707-714.	1.7	8
51	Nerve-Sparing Laparoscopic Colposacropexy Using a Percutaneous Surgical System: A Case Report. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 536-537.	0.6	7
52	Role of minimally invasive surgery versus open approach in patients with early-stage uterine carcinosarcomas: a retrospective multicentric study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 845-852.	2.5	7
53	Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD). <i>International Journal of Gynecological Cancer</i> , 2022, 32, 939-943.	2.5	7
54	Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD study): a collaboration of MITO, AIRO GYN, and MaNGO groups. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 732-739.	2.5	7

#	ARTICLE	IF	CITATIONS
55	Extreme complications related to bevacizumab use in the treatment of ovarian cancer: a case series from a III level referral centre and review of the literature. <i>Annals of Translational Medicine</i> , 2020, 8, 1687-1687.	1.7	6
56	PD-L1 Expression on Circulating Tumour-Derived Microvesicles as a Complementary Tool for Stratification of High-Grade Serous Ovarian Cancer Patients. <i>Cancers</i> , 2021, 13, 5200.	3.7	6
57	Endometrial Stromal Sarcoma Arising from Endometriosis. <i>Journal of Endometriosis and Pelvic Pain Disorders</i> , 2017, 9, 174-179.	0.5	5
58	Imaging modalities in fertility preservation in patients with gynecologic cancers. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 323-331.	2.5	5
59	<i>BRCA</i> status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 639-645.	2.5	5
60	Integration of PARP-inhibitors in ovarian cancer therapy. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, 171-182.	0.8	3
61	Comparison of Different Near-Infrared Technologies to Detect Sentinel Lymph Node in Uterine Cancer: A Prospective Comparative Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7377.	2.6	2
62	Use of Laparoscopic and Laparotomic J-Plasma Handpiece in Gynecological Malignancies: Results From A Pilot Study in A Tertiary Care Center. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
63	Response to: Correspondence on "ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors" by Thomassin-Nagarra et al. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1396-1397.	2.5	1
64	Comprehensive overview about ovarian cancer and secondary peritoneal tumors. <i>Minerva Medica</i> , 2019, 110, 277-278.	0.9	1
65	Nomogram to predict feasibility of minimally invasive interval debulking surgery in advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-002908.	2.5	1
66	Pegylated Liposomal Doxorubicin in the Management of Ovarian Cancer. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S4456.	0.4	0
67	Efficacy and safety outcomes in heavily pretreated patients (pts) with relapsed ovarian cancer (ROC) after single-agent trabectedin.. <i>Journal of Clinical Oncology</i> , 2013, 31, e16538-e16538.	1.6	0
68	Minimally invasive secondary cytoreductive surgery for hepato-renal recess isolated recurrence of serous endometrial cancer in BRCA1 mutated patient. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-003271.	2.5	0